Samsung BioLogics signed CDO(Contract Development Organization) contract with GI Innovation

May 03, 2019   |   May 2019 Bond Updates
SEOUL, South Korea, May 3, 2019 /PRNewswire/ -- Samsung BioLogics (CEO: Tae Han Kim) and GI Innovation (CEO: Soo Yeon Nam) signed a Contract Development Organization (CDO) contract for immunochemotherapy at Samsung BioLogics headquarters on Thursday. GI Innovation signed this second...

View more at:
Related News
Home| About us | Contact us